Promega, ATCC Partner on Bioassays for Biologics Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Promega and ATCC today announced a collaboration for cell banking and bioproduction of cells in order to create bioluminescence-based drug discovery assays for biologics.

The deal calls for ATCC to produce and authenticate cell banks and production lots of engineered and stock cell lines for use as cellular reagents as Promega creates a line of new cell-based assay systems for biologics. The initial system will be for biologics drug discovery.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic factors associated with facial features, a new mutation that makes individuals more prone to Brugada syndrome, and more.

Nutrigenomic companies offer gene-based diet advice, the Wall Street Journal reports.

Researchers have found a new kind of virus — one that starts out broken up into five parts.

Nature News explores the president's "science legacy."